Ozempic (semaglutide (T2D injection)): the 2026 GLP-1 guide

Overview

Ozempic is Novo Nordisk’s semaglutide subcutaneous injection, FDA-approved on December 5, 2017 for the treatment of type 2 diabetes, with a subsequent indication added for cardiovascular risk reduction in adults with T2D and established cardiovascular disease.

It is the same molecule as the injectable Wegovy, but at lower doses (max 2 mg weekly vs 2.4 mg) and with a T2D + CV-risk indication rather than chronic weight management. Insurance treats them as distinct products.

Clinical Efficacy

In SUSTAIN-6 (3,297 adults with T2D and high CV risk), Ozempic produced 1.8% A1c reduction and 4.9% body-weight loss over 104 weeks vs placebo. The trial’s primary endpoint was a 26% relative-risk reduction in major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke), which led to the cardiovascular risk-reduction indication¹.

For diabetes patients, Ozempic provides robust glycemic control with weight reduction and cardiovascular benefit — meaningful for patients with established CV disease but lower weight-loss efficacy than tirzepatide (Mounjaro) or higher-dose semaglutide (Wegovy Tablets).

Dosing & Titration

Four approved dose strengths, available as multi-dose pre-filled pens:

• 0.25 mg — starting dose, 4 weeks only (titration; not therapeutic)
• 0.5 mg — first maintenance dose
• 1.0 mg — common maintenance dose
• 2.0 mg — maximum approved dose for additional glycemic control

Schedule: start at 0.25 mg once weekly for 4 weeks. Increase to 0.5 mg after ≥4 weeks. May increase to 1 mg after ≥4 weeks at 0.5 mg, then to 2 mg after ≥4 weeks at 1 mg if additional glycemic control is needed. Inject in the abdomen, thigh, or upper arm².

Side Effects

Boxed warning — Risk of Thyroid C-Cell Tumors

In rodents, semaglutide causes thyroid C-cell tumors. Whether Ozempic causes the same (including medullary thyroid carcinoma, MTC) in humans is unknown. Ozempic is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)².

Most common adverse reactions (Ozempic 1.0 mg vs placebo)

GI events typically improve over the first 4–8 weeks of titration. Discontinuation rates due to GI events are 4–8%.

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known serious hypersensitivity to semaglutide or excipients

2026 Availability

Ozempic is widely covered as Part D Tier 4 for diabetes patients (95 plans indexed). Cash list price is approximately $998/month.

Ozempic is NOT included on the Medicare GLP-1 Bridge program — Bridge eligibility requires a chronic-weight-management indication. For weight-loss patients, the on-label oral options are Foundayo (~12% loss, $149/mo via LillyDirect) or Wegovy Tablets (~14%, $149/mo via NovoCare). The on-label injection is Wegovy (semaglutide 2.4 mg, separate brand) or Zepbound (tirzepatide).